New Drug Combines Hormones to Treat Obesity and Diabetes

New Drug Combines Hormones to Treat Obesity and Diabetes

Research on obesity – BC4625
Researchers from the Hemholtz Diabetes Center in Munich, Germany were able to successfully test a drug on rodents which reversed the effects of obesity and diabetes over the course of three weeks.  At the end of the study, the fat mass of the rodents dropped by a third and their blood glucose fell by half.  The drug is a combination of the hormones glucagon-like peptide (GLP-1), gastric inhibitory peptide (GIP) and glucagon, which are responsible for regulating blood sugar and appetite.  The newly created hybird-hormone would be able to stimulate chemical signals to trigger the body’s metabolism to lower blood glucose, burn fat, and lose weight. 
Bariatric surgery is typically reserved for patients suffering from life threatening obesity, and sometimes involves removing part of the stomach or small intestine to limit food intake.  Recent studies have shown that these procedures can alter the way hormones are released from the gut in order to stimulate weight loss.  This latest finding may be the first step in creating a drug with the benefits of weight loss surgery, without the risks associated with the operation.

About the Author: